Emergent BioSolutions is on a mission to promote its life-saving opioid overdose treatment, Narcan, and has enlisted former NFL star Emmitt Smith as a key ally in this endeavor. The Maryland-based company introduced an over-the-counter version of Narcan in August, emphasizing that anyone can be a potential lifesaver, whether at home, work, or while on the move with Narcan nasal spray. Now, they’ve teamed up with Emmitt Smith, the legendary running back who graced the Dallas Cowboys from 1990 to 2002, to amplify their message.
In a bid to spark vital conversations surrounding the perils of opioids and actions that can make a difference in overdose situations, Emergent and Smith are launching the “Ready to Rescue” campaign. This cause hits close to home for Smith, who has witnessed the devastating impact of accidental overdoses on teammates and experienced the agonizing struggle of family members battling addiction. Smith shared, “As a father of five, I make sure to talk to my kids about the risks associated with opioids, and I want to use my voice to help keep our loved ones and communities safe by urging everyone to have Narcan Nasal Spray on hand.”
Recognizing the urgency of reaching the younger population, Emergent is determined to make a difference, as opioid misuse and dependency are most pronounced among young adults aged 18 to 25. To achieve this, they are joining Smith in traveling to college football tailgates, those vibrant gatherings where people converge for pre-game festivities, munchies, and beverages.
The focus on tailgates is well-founded, as evidence suggests that student athletes and college campuses are particularly susceptible to opioid misuse and dependency, often driven by peer pressure, performance expectations, stress, and curiosity. At these events, Emergent will conduct Narcan demonstrations and distribute “Ready to Rescue” kits. These initiatives are set to take place at various locations across the United States throughout the month.
Emergent BioSolutions is strategically leveraging its pioneering status in the over-the-counter market, aiming to bolster Narcan sales, with a target range of $425 million to $445 million for this year. While companies like Teva and Hikma compete in the prescription space, Emergent enjoys a limited-time monopoly in the OTC realm. It’s noteworthy that Harm Reduction Therapeutics plans to introduce an over-the-counter opioid overdose remedy early next year, adding a new dimension to this evolving landscape.
